News from the healthcare data industry
Abstract Background: Clinical trials have shown immunotherapy (IO) to be more effective than chemotherapy in pre-treated, advanced non-small cell lung cancer (NSCLC). However, there is a lack of understanding of its...
Lugano, Switzerland, 23 March 2022 – More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the last five...
Abstract Aims: Using German claims, the authors replicated the CHAARTED trial in metastatic hormone-sensitive prostate cancer. Methods: The authors identified metastatic hormone-sensitive prostate cancer patients replicating the inclusion/exclusion criteria of CHAARTED. Patients treated...
February 26, 2022—Phoenix, Arizona—Use of benralizumab in patients aged 12 and over with severe eosinophilic asthma results in significant reduction in asthma exacerbations, oral corticosteroid use, and healthcare resources utilization,...
Background: Abiraterone and enzalutamide are widely used as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC); however, their efficacy in mCRPC has been inconsistently demonstrated in other outcome studies from real-world...
Ariel D Stern 1, Jan Brönneke 2, Jörg F Debatin 2, Julia Hagen 2, Henrik Matthies 2, Smit Patel 3, Ieuan Clay 4, Bjoern Eskofier 5, Annika Herr 6, Kurt Hoeller 7, Ashley Jaksa 8, Daniel B Kramer 9, Mattias Kyhlstedt 10, Katherine T Lofgren 11, Nirosha Mahendraratnam 12, Holger Muehlan 13, Simon Reif 14, Lars Riedemann 15, Jennifer C Goldsack 3 Affiliations 1Technology and Operations Management...
Abstract Osteoarthritis is a degenerative joint disease that affects millions of people worldwide. Current guidelines emphasize the importance of regular physical activity as a preventive measure against disease progression and...
Treatment with eribulin (Halaven) elicited an estimated 2-year overall survival (OS) rate of 53.6% (95% CI, 35.1%-68.9%) for patients with metastatic breast cancer (MBC) previously treated with atezolizumab (Tecentriq) or...
Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN...
Background To assess the performance of various coding algorithms for identifying people with hepatitis B virus (HBV) and hepatitis C virus (HCV) using claims data according to different reference standards...